Figure 1.

Clinical applications of cfDNA during the treatment process. Serial monitoring of ctDNA in plasma allows non-invasive identification of clinically relevant genomic alterations at different stages: molecular stratifications at diagnosis, tracking tumour responses during treatment, and identifying genetic mechanisms of resistance at progression. Colours represent tumour subclones with different mutations, which release ctDNA at different frequencies, as depicted in the graph below.